Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENS-111 single-dose motion exposure study
2018-000777-80Phase 2Completed
- Sponsor
- Sensorion
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of seliforant in motion sickness (4 arms), sponsored by Sensorion. Primary endpoint: Primary sedation-related performance endpoints. Started May 2018; status: completed.
02
Drugs
seliforant
03
Conditions
motion sickness
Beyond the preview
Go deeper on 2018-000777-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000777-80.